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COMPARATIVE  EVALUVATION  OF  SPINAL ANAESTHESIA  
WITH  LEVOBUPIVACAINE  AND HYPERBARIC BUPIVACAINE 
FOR  CAESAREAN SECTION  
ABSTRACT 
AIM&OBJECTIVES:  
This study was performed to compare the anesthetic efficacy and safety of two 
local anesthetic agents : hyperbaric bupivacaine and isobaric levobupivacaine, in 
patients undergoing elective caesarean section.    
METHODS AND MATERIALS:  
Sixty patients, ASA I-II, were randomized to receive an intrathecal injection of 
hyperbaric bupivacaine or isobaric levobupivacaine. Group B (n = 30) received 2 ml of 
Hyperbaric bupivacaine 5 mg/ml (10 mg). Group L (n = 30) received 2 ml of  isobaric 
levobupivacaine 5 mg/ml (10 mg).  
The onset and duration of sensory and motor blockade, recovery parameters, 
hemodynamic changes and side effects for the two agents were compared.   
RESULTS:  
The time of onset of sensory block was faster in Group B(1.46 ± 0.50) when 
compared with Group L(2.0 ± 0.37).  In Group B the time to two segment regression 
was prolonged (76.16 ± 13.86) when compared with Group L (68.43 ±12.96) and it is 
statistically significant. Duration of motor blockade was prolonged in Group B(132 ± 
7.67) when compared with Group L (99 ± 9.13). Hemodynamic variables were more 
stable in Group L than Group B. Twelve patients in Group B had adverse effects when 
compared with seven patients in Group L.     
CONCLUSION:  
0.5% Isobaric Levobupivacaine 10mg for intrathecal injection of caesarean section 
produces adequate sensory and motor blockade and stable hemodynamic parameters 
with minimum adverse effects than 0.5% hyperbaric bupivacaine 10mg.  We concluded 
that isobaric Levobupivacaine is a better alternative for caesarean section. 
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INTRODUCTION 
Spinal anaesthesia was introduced into clinical practice by Karl August Bier 
in 1898. More than a century has passed and even today, it is one of the most 
popular techniques for both elective and emergency surgical procedures 
particularly Caesarean Sections, lower abdominal surgeries, orthopaedic and 
urological surgeries just to name a few. 
Spinal anesthesia used for providing a fast onset and effective sensory and 
motor blockade bupivacaine is available as a racemic mixture of its enantiomers, 
(dextrobupivacaine and levobupivacaine) .  
Levobupivacaine is an effective long acting amide local anaesthetic 
produced as a pure enantiomer. The sensory block is similar to that produced by 
an equivalent dose of bupivacaine. However, the motor block provided is of slower 
onset, lesser intensity and of shorter duration. 
 Levobupivcaine is an L enantiomer of bupivacaine.When administered for 
caesarean section it has been shown to have motor blockade of lesser intensity 
when compared to bupivacaine. It is considered more potent than ropivacaine due 
to its greater lipid solubility.3 
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The reduced toxic potential of both the above mentioned drugs is strongly 
supported by animal and volunteer studies, which report higher plasma 
concentrations before signs of systemic toxicity appear and also a higher success 
rate of cardiopulmonary resuscitation in cases of cardiac collapse.In our study we 
will compare the clinical effects of two drugs levobupivacaine and bupivacaine in 
spinal anaesthesia for elective caesarean section. 
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AIM OF THE STUDY 
To compare the following factors in two groups (0.5%hyperbaric 
Bupivacaine 10mg) and (0.5% isobaric Levobupivacaine 10mg) for elective 
caesarean sections under spinal anaesthesia, with respect to:  
1. Sensory blockade - Onset, Time to peak sensory blockade, highest level of 
sensory block. 
2. Motor blockade - Onset, Time to maximum motor blockade, duration of motor 
block. 
3. Recovery parameters - Time to two segment regression, time to complete 
sensory and motor recovery.  
4.  Hemodynamic changes  
5.  Adverse effects   
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HISTORY 
1884 - Koller, demonstrated local analgesic properties of cocaine  
1885 - JlL Corning, produced analgesia by accidental subarachnoid 
injection of cocaine 
1892 - Heinrich Braun introduced the term ‘conduction anaesthesia 
1898 - August Bier, introduced first clinical spinal analgesia 
1901 - Extradural caudal injection, introduced by Sicard and Cathelin, 
independently. 
1902 - Heinrich Braun, added adrenaline to cocaine, to prolong its effects 
and retard its absorption. 
1906 - Haubold and Meltzer – Intrathecal administration of magnesium 
Sulphate 
1917 - Edmund Boyle described his portable N2O and O2 apparatus. 
1921 - Extradural lumbal analgesia described by Pages. 
1947 - Lignocaine was introduced by Torsten Gordh. 
1957 - Ekenstam synthesized Bupivacaine 
1963 - Bupivacaine was used clinically by LJ telivuo 
1966 - Ketamine used clinically by Corssen and Domino. 
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ANATOMICAL CONSIDERATION 
 
 Spinal anaesthesia was initially produced inadvertently by J.L.Cornings in 
1885, and first used deliberately by August Bier in 1898.  Lumber subarachnoid 
block is a safe and simple clinical procedure and is to be preferred to general 
anaesthesia for certain operations and in certain groups of patients. 
 
Vertebrae 
 They are 33 in number, seven cervical, twelve thoracic, five lumbar, five 
sacral and four coccygeal, each being composed of body, separated by 
intervertebral discs.  ‘Vertebral arch’ formed by pedicles and laminae, transverse 
and spinous processes with attached ligaments and muscles and articular 
processes. 
 
Vertebral canal 
 Formed by these structures, vertebral canal has deficiencies laterally 
between intervertebral foramen and posteriorly between interlaminar foramen 
which enlarges in flexion and accessible for spinal needle.  The direction of 
spinous processes determines the direction of spinal needle.  
From skin onwards spinal needle pierces through subcutaneous tissue, supra and 
inter spinous ligaments, ligamentum flavum and dura before reaching 
subarachnoid space.  Piamater is closely applied to spinal cord. 
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 Ligamentum Flavum 
 Ligamentum flavum is important to anaesthesiologists.  It is composed of 
yellow elastic fibres running between lower border of lamina above and upper 
border of lamina below. 
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Spinal cord 
 Spinal cord is a direct continuation of medulla oblongata extending from 
upper border of atlas to first lumber vertebra, below which there is a leash of nerve 
roots termed ‘Cauda Equina’. 
Spinal Nerves and Spinal segments 
 Spinal nerves are 31 pairs, eight cervical, twelve thoracic, five lumbar, five 
sacral and one coccygeal, each composed of anterior and posterior rami uniting at 
the intevertebral foramen to form nerve trunk. 
Coverings of the spinal cord from outside are; 
 Duramater is composed of outer periosteal layer, in continuation with 
periosteum of skull, and inner investing layer attached to foramen magnum 
preventing spread of drug at the epidural space above first cervical vertebra. 
Arachnoid mater is continuous above into cranium. 
Dura and arachnoid end as tube at S2 level, hence CSF is not found below 
this level. 
Piamater is closely applied to the spinal cord and is highly vascular. 
 
Blood supply of Spinal Cord 
Blood supply of spinal cord is through a single anterior spinal artery arising 
by union of a small branch from each vertebral artery and it supplies the lateral 
and the anterior columns.  Two posterior spinal arteries on each side which are 
branches of posterior inferior cerebellar arteries with no anastamosis between 
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them, supply the posterior columns of the cord.Spinal Veins comprise of anterior 
and posterior plexuses draining into vertebral, azygos and lumbar veins. 
Cerebro Spinal Fluid (CSF) 
 CSF is a clear liquid with PH of 7.4.  It is produced as a selective filtrate by 
the choroid plexuses of lateral ventricles, passes through the interventricular 
foramina (of monro) into the third ventricle then through the cerebral aqueduct (of 
sylvius) into the fourth ventricle.  CSF reaches the spinal subarachnoid space 
through foramen of Magendie and foramen of Luschka.  Amount in spinal canal 
is 75 ml with a pressure of 70-180 mm of H2O in lateral position and 375-500mm 
of H2O in vertical position.  Normal contents are protein 20-40 mg%; sugar 45-80 
mg% and cells 0-5 lymphocytes. An important factor that determines the spread 
of drug in CSF is the specific gravity of the drug in relation to that of CSF, which 
is 1.003 – 1.009 (average 1.004).  Hyperbaric solution is one which is denser than 
CSF at C.  The Specific gravity of 10% Dextrose, such as is commonly included 
in the so called heavy or hyperbaric solutions is 1.034. 
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APPLIED ANATOMY OF PREGNANCY 
 
VERTEBRAL ANATOMY: 
 In women of child bearing age, the spinal cord terminates as conus 
medullaris at the level of the lower border of the first lumbar vertebral body.  The 
conus medullaris is attached to the coccyx by means of neuro-fibrous band called 
the filum terminale, which is surrounded by the nerves of the lower lumbar and 
sacral roots known as cauda equine. 
The subarachnoid space located between the pia mater and arachnoid mater, 
contains (1) Cerebrospinal fluid (CSF) (2) spinal nerves (3) Trabecular network 
between the two membranes (4) Blood vessel that supply the spinal cord and (5) 
The lateral extension of pia mater – the denticulate ligament. The Normal anatomic 
changes of pregnancy affect the use of neuraxial technique.  Uterine enlargement 
and venacaval compression result in engorgement of epidural veins.  The enlarged 
epidural veins also may displace cerebrospinal fluid (CSF) from the thoracolumbar 
region of the subarachnoid as does the greater intra-abdominal pressure of 
pregnancy.  This displacement of CSF and lower specific gravity of CSF, partly 
explains lower dose required for spinal anesthesia in pregnant patients. 
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Effect of pregnancy on lumbar spine: Fig A, Non pregnant. B, pregnant 
there is a marked increase in lumbar lordosis and a narrowing of the interspinous 
space during pregnancy. 
The hormonal changes of pregnancy affect the perivertebral ligamentous 
structures, including ligamentum flavum.  The ligamentum flavum feels less dense 
and softer in pregnant women than in non pregnant. 
Achieving flexion of the lumbar spine is difficult for pregnant women.  
Progressive accentuation of lumbar lordosis alter the relationship of surface 
anatomy to the vertebral coloum.  The changes that my occur in pregnancy are 
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• A pregnant women pelvis rotates on the long axis of the spinal column, thus 
the line joining the iliac crest assume a more cephalad relationship to the 
vertebral column. 
• There is less space between adjacent lumbar spinous processes during 
pregnancy.  It may be more difficult to use the midline approach to indentify 
the epidural or subarachnoid space in pregnant women. 
• MRI imaging has shown that the apex of the lumbar lordosis is shifted 
caudal during pregnancy, and the typical thoracic kyphosis in women is 
reduced during pregnancy.  These changes may influence the spread of 
intrathecal anesthetic solution in supine patient. 
• Pelvic widening and resultant head-down tilt in the lateral position 
during pregnancy. 
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Anatomical changes in respiratory system: 
 During pregnancy the thoracic cage increases in both the anteroposterior 
and transverse diameters by which circumference also increases by 5 to 7 cm .At 
the end of the first trimester flaring of the ribs results in an increase in the sub 
costal angle from 68.5 to 103.5 degrees at term.  Because of elevated position of 
the diaphragm vertical measurement of the chest decreases by as much as 4 cm. 
 Capillary engorgement of the nasal and oropharyngeal mucosae and larynx 
begins early in the first trimester and increases progressively throughout 
pregnancy.  Nasal breathing commonly becomes difficult, and epistaxis may occur 
because of nasal mucosal engorgement. 
             Airway conductance increases, indicating a dilation of the larger airways 
below the larynx.  Factors contributing to airway dilation include the direct effects 
of progesterone, cortisone, and relaxin. 
 
Anatomical changes in Gastrointestinal system: 
  The stomach is displaced upward toward the left side of the diaphragm 
during pregnancy, and its axis is rotated approximately 45 degrees to the right from 
its normal vertical position.  The altered position of the stomach displaces the 
intra-abdominal segment of the esophagus into the thorax.  This causes a reduction 
in tone of the lower esophageal high-pressure zone (LEHPZ), which normally 
prevents the reflux of gastric contents.  This displacement of the esophagus also 
prevents the rise in lower esophageal tone that normally accompanies an increase 
in intragastric pressure (IGP).  Progestins also may contribute to a relaxation of 
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the LEHPZ IGP is elevated during the last trimester in all pregnant women.  These 
anatomical changes predispose to increased risk of aspiration. 
Feto-placental unit: 
 The placenta is composed of both maternal and fetal tissues that consist of 
a basal and a chorionic plate, It is semi permeable membrane that provides an 
interface for the maternal and fetal circulation.  The intervillous space separates 
the plates and is subdivided by decidual tissue.  Chorionic villi and spiral arteries 
protrude into this intervillous space.Maternal blood flows into the intervillous 
space from the spiral artery while placental transfer from the mother to the fetus 
occurs.Approximately 80% of the uterine blood flow passes through the 
intervillous space.  
 
                                
     
Oxygenated blood leaves the placenta through fetal umbilical vein, enters 
the liver where flow divides between portal sinus and ductus venosus then empties 
into IVC.  Inside the fetal heart, blood enters the right atrium through foramen 
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ovale, where most of the blood is directed into left atrium and left ventricle, and 
then enters aorta.  Blood is then sent to the brain and myocardium.  Deoxygenated 
blood returning from lower extremities and SVC is preferentially directed into 
right ventricle and pulmonary trunk, majority of blood passes through ductus 
arteriosus into descending aorta.  Blood returns to the placenta through umbilical 
arteries for gas and nutrient exchange.  Fetal blood flow is approximately 75 
ml/kg/min, a rate far less than maternal flow. 
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APPLIED PHYSIOLOGY OF PREGNANCY 
 
Physiological changes in Pregnancy 
 There are considerable physiological changes in parturient which can affect 
the anaesthesia technique. 
Cardiovascular System 
• Intravascular fluid volume  - by 35% 
• Cardiac output    - by 40% 
• Systemic vascular resistance  - by 15% 
• Heart rate     - by 15% 
• Systolic blood pressure   - No change 
Increase; : Decrease 
 The implication is that these patients due to hyperdynamic circulation can 
develop congestive heart failure. 
Aortocaval Compression: 
 In supine position, gravid uterus compress the aorta and inferior vena cava 
leading to decreased venous return.  Venous return occurs primarily by diversion 
of blood through the intraosseous vertebral veins, paravertebral veins, and epidural 
venous plexus.  This drop in venous return for which the cardiovascular system 
cannot compensate could result in supine hypotensive syndrome. 
16 
 
 
Respiratory System: 
Tidal volume    - by 40% 
Respiratory rate    - by 10% 
Minute ventilation    - by 50% 
Functional residual capacity  - by 20% 
Functional residual capacity  
Expiratory reserve volume- (due to gravid uterus causing diaphragmatic  
Residual volume   elevation) 
Vital capacity lung volume - No changes 
Airway resistance   - by 35% 
Oxygen consumption  - by 20% 
Blood gases 
paO2  by 10mmHg - Due to 
pCO2  by 10mmHg - hyperventilation  
Ph            - No change due to compensatory mechanism  
17 
 
Anaesthetic Implications of Respiratory Changes 
 
• Due to increased minute ventilation the induction with inhalational agents 
is faster and dose requirement is less making pregnant patients more 
susceptible to anaesthetic over dosage. 
• Due to decreased FRC, ERV and increased oxygen requirement these 
patients are more vulnerable for hypoxia so preoxygenation is very 
important. 
• Due to capillary engorgement in upper airways chances of trauma and 
bleeding during intubation are high. 
• Laryngeal edema may be a prominent feature in PH patients, making 
intubation difficult. 
Nervous System 
• Progesterone has got sedative effect decreasing the anaesthetic 
requirement by 25 to 40%. 
• Since epidural veins are in direct communication with inferior vena cava 
therefore compression of inferior vena cava by gravid uterus leads to 
engorgement of epidural veins which decreases subarachnoid space 
leading the drugs to spread higher.  Because of this pregnant patients are 
vulnerable for high spinal.  Therefore, to prevent high spinal the dose of 
local anaesthetic for spinal has to be reduced by 30 to 40%. 
GIT  
 Parturient are very vulnerable for aspiration due to the following reasons: 
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• Gastric emptying is delayed due to progesterone. 
• Gravid uterus alters the normal gastro esophageal angle making lower 
esophageal sphincter (LES) incompetent. 
• Progesterone relaxes the LES. 
• Gastric contents are more acidic. 
 
Anaesthetic Implications 
 A pregnant patient should be considered full stomach even if she is fasting 
and     must be managed like a high risk case for aspiration. 
 
Hepatic System 
Plasma cholinesterase level is decreased by 25% prolonging the effect of 
SCH. 
 
Kidneys 
Because of increase in cardiac output there is increase in renal blood and 
GFR. 
 
Uterus 
If a pregnant patient lies in supine position gravid uterus can compress the 
inferior vena cava and aorta decreasing the cardiac output and blood pressure 
causing supine hypotension syndrome (SHS) and this can cause severe 
hypotension or even cardiac arrest after spinal anaesthesia. 
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To prevent this the pregnant patient should lie in left lateral position.  This can be 
accomplished by: 
• Putting a wedge under right buttock. 
• Tilting the delivery table by to left. 
• Manually displacing the uterus to left. 
Uteroplacental circulation and anaesthetic drugs 
Uterine blood flow is 500 to 700 ml/min (10% of cardiac output) and 
placental flow is directly dependent on maternal blood flow. 
• Hypotension and drugs causing vasoconstriction can severely compromise 
fetal wellbeing. 
• Positive pressure ventilation (IPPV) can decrease cardiac output by 
decreasing venous return and thus can compromise Placental blood flow. 
• Inhalational agents in higher concentration can compromise uterine flow by 
their effect of producing hypotension and decreased cardiac output. 
• Intravenous agents: Thiopentone and propofol decrease uterine blood flow 
in proportion to decrease in blood pressure.  Ketamine by producing uterine 
hypertonicity can decrease the uterine blood flow. 
Spinal / epidural anaesthesia can compromise uterine blood flow by 
producing hypotension. 
Transfer of Anaesthetic drugs to fetal circulation 
 All anaesthetic drugs except muscle relaxants (only gallamine has 
significant transfer) and glycopyrrolate can be transferred to fetus from 
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maternal circulation.  So all drugs should be used in minimum concentration 
and dosage. 
• A large fraction of drug which is coming from placenta to fetus is 
metabolized by fetal liver (75% of umbilical vein blood flows through 
liver), so less drug reaches to vital structures like brain and heart.  This 
is a protective mechanism but drugs like local anaesthetics and opioids 
which are bases, cross the placenta in unionized form, become ionized 
in fetal circulation (which has low pH) and cannot come back to 
maternal circulation leading to accumulation in fetus. 
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PHARMACOLOGICAL CHANGES IN PREGNANCY 
 
PHARMACODYNAMICS OF LA 
 Pregnant women require small doses of local anesthetics due to epidural 
venous engorgement, enhance neural sensitivity to local anesthetics higher PH 
lower bicarbonate and total Carbon dioxide content in CSF in women undergoing 
caesarian section. 
PHARMACOKINETICS OF LA: 
 Bupivacaine is the most commonly used local anesthetic in obstetric 
anaesthesia because it preserve motor function and is compatible with intrathecal 
opioids.  It bound extensively by two proteins, both of which decline during 
pregnancy: (1) alpha-1-acid glycoprotein (AAG), a high-affinity, low-capacity 
site, and (2) albumin, a low-affinity, high-capacity site. 
PREECLAMPSIA AND LA DRUGS 
In preeclampsia reduced hepatic blood flow, abnormal liver function and 
decreased intravascular volume affect, maternal blood concentration of local 
anesthetics.  Long acting amides have a relatively low hepatic extraction ratio, 
changes in liver blood flow in preeclampsia may have less effect on the metabolic 
clearance. 
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Effect on Uterus: 
 Pregnancy may enhance uterine vascular reactivity to local anesthetic 
agents. 
Effect on umbilical blood flow: 
 Bupivacaine does not constrict umbilical artery at clinically relevant 
concentration of 0.3-1 mcg/ml.  At higher concentration the effect of bupivacaine 
appear to be biphasic.  5-10 mcg.ml produce uterine artery constriction more than 
125 mcg/ml produce relaxation of artery. 
S/D ratio (systolic peak to diastolic trough of the umbilical artery) in the umbilical 
artery decreases during normal pregnancy and high ratio usually are associated 
with fetal compromise. 
Placental drug transfer: 
Factor affecting placental transfer of drugs include 
• Physiochemical characteristic of local anesthetic agent 
• Concentration of free drug in mater 
• Permeability of the placenta 
• Hemodynamic events occurring within the fetal maternal unit 
During pregnancy, anatomic adaptations result in substantial (near 
maximal) vasodilation of the uterine spiral arteries, this result in a low-resistance 
pathway for the delivery of blood to the placenta.  Therefore, adequate 
uteroplacental blood flow depends on the maintenance of a normal maternal 
perfusion pressure. Physical factors (e.g., molecular weight, lipid solubility, 
degree of ionization) affect the placental transfer of drugs and other substances.  
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In addition, other factors affect maternal – fetal exchange, including changes in 
maternal and fetal blood flow, placental binding, placental metabolism, diffusion 
capacity, and degree of maternal and fetal plasma protein binding. 
Lipophilicity, which enhances the central nervous system uptake of general 
anesthetic agents, also heightens the transfer of these drugs across the placenta.  
Fetal acidemia can result in the so-called “ion trapping” of both local anesthetics 
and opiods. 
Molecular size: 
Compound with a molecular size less than 1000 Daltons crosses the 
placenta easily. 
Ionization and lipid solubility: 
 The degree of ionization affect the rate of placental diffusion because the 
unionized molecule is more lipid soluble than ionized molecule. 
Protein binding: 
 Bupivacaine in the maternal plasma is 2 mg/L. bupivacaine are 
approximately 90% bound to maternal plasma proteins, the free concentration of 
drug available for placental transfer is 0.2 mg/L.  At equilibrium, the concentration 
of free drug is equal on both sides of the placenta.  However, in the fetus, 
bupivacaine 50% bound to fetal plasma proteins, Total bupivacaine, and the 
concentration in fetal plasma is 0.4 mg/L and an F/M ratio of 0.2. 
Transfer across the placenta may be reported as drug clearance or as a ratio 
that is also referred to as the transfer index used to improve interplacental 
comparisons. 
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Teratogenicity: 
 Local anesthetics used during the first trimester of pregnancy caused 
reversible reduction of cell division in tissue culture.  Large multicenter study 
demonstrated that the risk of congenital anomalies in humans was not increased 
by the administration of benzocaine, procaine, tetracaine, or lidocaine during early 
pregnancy.  However, a twofold increase in the incidence of congenital anomalies 
was noted in infants whose mothers had received mepivacaine. 
FETUS AND NEWBORN: 
Pharmacokinetics: 
 Local anesthetics, once transferred across the placenta, are distributed in 
the fetus.  Factors that influence tissue uptake of the drug include (1) fetal plasma 
protein binding, (2) lipid solubility, (3) the degree of ionization of the drug, and 
(4) hemodynamic changes that affect the distribution of fetal cardiac output. 
The term newborn has the hepatic enzymes necessary for the biotransformation of 
amide local anesthetics.  The elimination half-life of these drugs is longer in the 
neonate compared with the adult.  The use of mepivacaine in obstetric epidural 
analgesia elimination half-life of the drug in the newborn was approximately 9 
hours. 
SYSTEMIC TOXICITY: 
 Changes in fetal heart rate (FHR) after administration of local anesthetics 
most often are related to indirect effects such as maternal hypotension and uterine 
hyperstimulation.  FHR patterns are not affected by the larger doses of local 
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anesthetics required during administration of epidural anesthesia for cesarean 
delivery. 
PRETERM FETUS AND NEWBORN: 
 Enhanced drug sensitivity in the preterm newborn: (1) less protein is 
available for drug binding; (2) higher levels of bilirubin are present and may 
compete with the drug for protein binding; (3) greater drug access to the CNS 
occurs because of a poorly developed blood-brain barrier; (4) the preterm infant 
has greater total body water and less fat content; and (5) the preterm infant has a 
decreased ability to metabolize and excrete drugs. 
The placenta efficiently eliminates fetal bilirubin.  Thus the 
hyperbilirubinermia of prematurity normally occurs in the postpartum period.  
Bupivacaine has been implicated as a possible cause of neonatal jaundice.  High 
affinity of the drug for fetal erythrocyte membranes may lead to a decrease in 
filterability and deformability, which may render red blood cells more prone to 
hemolysis. 
Asphyxia: In asphyxiated preterm fetus, exposure to bupivacaine reduced blood 
flow to vital organs however, fetal heart rate, blood pressure, and acid-base 
measurements did not change Johnson et al. suggested that bupivacaine might be 
preferable to lidocaine in the presence of fetal acidosis because the greater 
maternal protein binding of bupivacaine may limit its placental transfer. 
Pharmacokinetic Principles: 
 Transfer of a drug that is highly protein bound is affected by the 
concentration of both maternal and fetal plasma proteins.  The pKa of a drug 
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determines the fraction of drug that is nonionized at physiologic pH.  Thus, fetal 
acidemia will greatly enhance the maternal-to-fetal transfer (i.e., “ion trapping”) 
of many basic drugs, such as local anesthetics and opioids.   
Factor affecting placental transfer of drug (maternal to fetal) 
 Increased transfer Decreased transfer 
Size – Mol. 
Weight (Dalton) 
<1000 >1000 
Charge of molecule Uncharged Charged 
Lipid solubility Lipophilic Hydrophilic 
PH vs drug Pka Higher proportion 
of un-ionised drug 
in maternal plasma 
Higher proportion of 
ionized drug in maternal 
plasma 
Placental efflux transporter 
proteins(e.g. P 
glycoprotein) 
Absent Present 
Binding protein type Albumin (lower 
binding affinity) 
Alpha-1-acid glycoprotein 
(AAG) higher binding 
affinity 
Free (unbound) drug 
fraction 
High Low 
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ANESTHETIC DOSE REQUIREMENT: 
 The effects of pregnancy on local anesthetic potency may reflect a 
combined effect of mechanical factors associated with pregnancy (i.e., dilated 
epidural veins decrease the volume of the epidural and subarachnoid spaces) and 
direct effects of hormones, especially progesterone, on the susceptibility of nerves 
to conduction blockade by local anesthetics per se.  Hormonal alterations are 
probably the more important of these two factors because greater spread of 
epidural anesthesia occurs during the first trimester of pregnancy, before any 
grows change in vascular dimensions within the epidural or subarachnoid spaces.  
The dosage of local anesthetics should probably be reduced in patients in all stages 
of pregnancy. 
 Pregnancy enhances the spread of hyperbaric local anesthetic solution in 
the subarachnoid space, resulting in a 25% reduction in the segmental dose 
requirement (i.e., milligrams of drug necessary to block one spinal segment) in 
term pregnant women. 
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 PHARMACOLOGY OF BUPIVACAINE 
Bupivacaine, an amide local anaesthetic was synthesized in Sweden by 
Ekenstam and his colleagues in 1957.  It was introduced into clinical practice by 
L.J.Telivuo in 1963. 
                                            Structure: 
                                 
 
Molecular formula: 
1-butyl-n-(2,6-dimethylphenyl) piperidine-2-carboxamide  
Physico chemical Properties: 
Molecular Weight    : 288 (base) 
      : 324 (HCL Salt) 
pKa at C     : 8.1 
Hydrophobicity at C             : 3420 
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PH of 0.5% solution              : 3.5 
Percentage of protein binding  : 96% 
Plasma protein binding   : 2 microgm/ml 
Lipid solubility    : 28 
Partition coefficient              : 27.5 (n-Haptane pH 7.4 buffer) 
Approximate anaesthetic duration       : 175min 
Site of metabolism    : liver 
Safe dosage     : 2mg / kg 
Conduction blocking potency  : 4 times more than that of lignocaine 
Maximum infuslon rate   : 0.4 mg/kg/hr 
Maximum single dose for infiltration : 175 mg. 
t½α                      t½β                    t½γ                  V                  clearance             
2.7 min                28 min              3.5 hrs               72L                    0.47L/min 
 
Mechanism of action: 
Bupivacaine action is similar to other local anesthetics, it produces 
electrical stabilization by acting on axonal cell membrane and produces 
conduction blockade by inhibition of sodium channels. 
Metabolism: 
 Possible pathways of metabolism include aromatic hydroxylation, N-
dealkylation, amide hydrolysis and conjugation in liver.  Only the N-desbutyl 
bupivacaine has been measured in blood or urine.  Alpha-1-acid glycoprotein is 
the most important plasma protein binding site of bupivacaine. 
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Main Anaesthetic Utility: 
It is used in infiltration peripheral nerve blockade, spinal and epidural anaesthesia. 
Pharmacodynamics: 
Cardiovascular system: 
 The primary electrophysiological effect is a decrease in the maximum rate 
of depolarization and due to an interaction with the fast sodium channels in cardiac 
membrane.  Action potential duration and effective refractory period are also 
decreased.  But the ration of effective refractory period to action potential duration 
is increased both in purkinje fibres and in ventricular muscle.  It exerts a dose 
dependent negative inotropic action.  Bupivacaine decrease ventricular 
contractility. 
Central Nervous System:  
Bupivacaine readily crosses the blood brain barrier causing CNS 
depression following higher doses. The initial symptoms involve feeling of 
light-headedness and dizziness followed by visual and auditory disturbances. 
Disorientation and drowsiness may occur. Objective signs are usually 
excitatory in nature, which includes shivering, muscular twitches and 
tremors, initially involving muscles of the face (perioral numbness) and part 
of extremities.   
Autonomic nervous system:  
Bupivacaine does not inhibit the Noradrenalin uptake and hence has no 
sympathetic potentiating effect. Myelinated preganglionic B fibers have a faster 
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conduction time and are more sensitive to action of Bupivacaine. When used for 
conduction blockade, all local anesthetics, particularly Bupivacaine produces 
higher incidence of sensory than motor fibers. 
Respiratory System:  
Respiratory depression may be caused if excessive plasma level is reached 
which in turn results in depression of medullary receptor center. Respiratory 
depression may be also caused by paralysis of respiratory muscles of diaphragm 
as may occur in high spinal or total spinal anesthesia. 
 Peripheral vascular system: 
 Biphasic action on smooth muscle was demonstrated with bupivacaine.  At 
low dose, it decreases peripheral arterial blood flow without changing blood 
pressure, whereas in high dose increases blood flow. 
Toxicity: 
 It is relatively free of side effects, if it is administered in an appropriate 
dosage and in the correct anatomic location. 
The toxic plasma concentration of bupivacaine is 4-5 mic/ml 
 Systemic toxicity reactions primarily involve CNS and CVS.  The blood 
level required to produce CNS toxicity is less than that required of circulatory 
collapse. 
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CNS toxicity: 
 Initial symptoms include feeling of light headedness and dizziness, 
followed by visual and auditory disturbances.  Objective signs are excitatory and 
include shivering, muscle twitching and tremors.  Ultimately, generalized tonic 
clonic seizures can occur.  The typical plasma concentration of bupivacaine 
associated with seizures is 4.5 to 5.5 microgm / ml. 
CVS toxicity: 
 The rate of depolarization in fast conduction tissues of purkinje fibres and 
ventricular muscle is decreased.  The rate of recovery of bupivacaine induced 
block is slower than that of lignocaine.  Extremely high concentration cause sinus 
bradycardia and cardiac arrest.  R-enantiomer is more toxic than S-enantiomer. 
CC/CNS ratio is 3.7 ± 0.5 
Neurotoxicity:   Placement of bupivacaine into epidural space can cause 
neurotoxicity.  Whose spectrum may range from patchy groin numbness and 
persistent isolated myotomal weakness to cauda equine syndrome. 
Allergy: 
 Although uncommon, allergic reactions can occur due to methyl paraben, 
the preservative.  
Fate of bupivacaine in the subarachnoid space 
 After injection of bupivacaine (Hyperbaric) 0.5% into the subarachnoid 
space it gets mixed with CSF.  The ‘DISTRIBUTION’ of bupivacaine within the 
CSF determines the ‘amount of the neural blockade’.  Distribution of hyperbaric 
solutions is governed by position of the patient during injection and for the next 
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20-30 mins.  The total dose is more important than volume (or) concentration of 
bupivacaine in determining spread in CSF. 
 ‘UPTAKE” occurs into the spinal nerve rootlets and slow diffusion via 
subarachnoid extensions accompanying blood vessels into cord (Virchow-Robin 
spaces).  The level of anaesthesia is said to be fixed, when changes in position of 
the patient no longer influence the distribution of the drug in CSF. 
Elimination 
 It is eliminated from CSF by vascular absorption via subarachnoid and 
epidural blood vessels. 
Metabolism 
 No significant metabolism of bupivacaine occurs in CSF.  After absorption, 
they bind with plasma proteins and then slowly taken up by tissues.  It is 
metabolized in the liver by N-dealkylisation and hydroxylation and small 
percentage is excreted in urine. 
Dosage depends on:  
• Area to be anaesthetized  
• Number of nerve segments to be blocked  
• Individual tolerance  
• Technique of local anaesthesia  
• Vascularity of area  
Bupivacaine is available in the following concentrations:  
• 0.25%. 0.5%and 1%  
• 0.25% and 0.5% solution in isotonic saline 
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• 0.5% solution in 8% dextrose  
Dosage is 2mg/kg limited to 150 mg in four hours. The intrathecal minimum local 
analgesic dose of Bupivacaine is 2.37 mg.   
Type of block  Concentration  Dosage in ml  Dosage in mg  
Sub arachnoid block  0.5 – 0.75%  02-04  10-20  
Epidural block  0.25 – 0.5%  15 – 30  50 - 200  
Caudal block   0.25 – 0.5%   15 - 30   75 – 150  
Brachial plexus 
block   
0.25 – 0.5%   15 – 30  75 – 225  
Intercostals nerve 
block   
0.25 – 0.5%  3 – 5 /ml   15 – 20  
Local infiltration   0.25 – 0.5%   5 – 20   Upto 175 mg  
 Adverse effects: 
CNS:   
 Nervousness, dizziness, blurring of vision or tremors, followed by 
drowsiness, convulsion, unconsciousness and respiratory arrest. 
CVS: 
Myocardial depression, hypotension, arrhythmia, ventricular type 
conduction defect, SA node depression and cardiac arrest. 
Allergic Reactions   :   Utricaria, bronchospasm, hypotension 
OTHER  :     Nausea, vomiting, chills, constriction of pupil and tinitus. 
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                        PHARMOCOLOGY OF LEVOBUPIVACAINE 
 
Levobupivacaine, (2s-1-butyl-N-(2,6-dimethyipheny) piperidine-2- 
carboxamide ,an amide local anaesthetic belongs to alkyl substitute 
pipecoloxylidide family,  it is an S enantiomer of racemic bupivacaine,since it dose 
not contain R isomer cardiotoxicity and neurotoxicity is lesser than bupivacaine. 
It produces similar sensory and motor blockade like bupivacaine. 
 
                                                      Structure:                        
 
 
CHEMICAL FORMULA    C18 H28 N2 O .   
Physico chemical Properties: 
Molecular Weight    : 288 (base) 
pKa at C     : 8.1 
pH of 0.5% solution              : 4.5-6 
solubility in water                                     : 25mg/ml 
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Percentage of protein binding            : 97% 
Lipid solubility    : 30 
Partition coefficient                : 346 
Site of metabolism                : liver 
Safe dosage                 : 2mg / kg 
Maximum single dose for infiltration   : 175 mg. 
volume of distribution                                 : 66.91 ±18.23 L 
Half life                                                       : 157 min 
Clearance                                                     : 0.32 
Metabolism: 
  Levobupivacaine extensively in liver with no or unchanged form appear in 
urine and faeces. The cytochromes CYP3A4 and CYP1A2 converts 
levobupivacaine metabolism to desbutyl levobupivacaine and 3-hydroxy 
levobupivacaine, appears to undergo further transformation to glucuronide and 
sulphate conjugates. Alpha-1-acid glycoprotein is the most important plasma 
protein binding site of levobupivacaine. 
Main Anaesthetic Utility: 
Surgical anaesthesia 
- Major, e.g. epidural (including for caesarean section), intrathecal, peripheral 
nerve block. 
- Minor, e.g. local infiltration, peribulbar block in ophthalmic surgery. 
Pain management 
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- Continuous epidural infusion, single or multiple bolus epidural administration 
for the management of pain especially post-operative pain or labour analgesia. 
Paediatric population 
Analgesia (ilioinguinal/iliohypogastric blocks). 
No data are available in paediatric population < 6 months of age. 
Pharmacodynamics: 
Cardiovascular system: 
 Levobupivacaine is a long acting local anaesthetic and analgesic, It blocks 
nerve conduction in sensory and motor nerves largely by interacting with voltage 
sensitive sodium channels on the cell membrane, but also potassium and calcium 
channels are blocked. The primary electrophysiological effect is a decrease in the 
maximum rate of depolarization and due to an interaction with the fast sodium 
channels in cardiac membrane.  Action potential duration and effective refractory 
period are also decreased.  But the ration of effective refractory period to action 
potential duration is increased both in purkinje fibres and in ventricular muscle.  It 
exerts a dose dependent negative inotropic action.  levobupivacine decrease 
ventricular contractility but it is less when compared with bupivacine. The safety 
margin is estimated at 1.3 which means that toxic effects are not seen until the 
concentration rises by 30% . 
Peripheral vascular system: 
 Biphasic action on smooth muscle was demonstrated with levobupivacaine.  
at low dose, it decreases peripheral arterial blood flow without changing blood 
pressure, whereas in high dose increases blood flow. 
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Nervous System: 
 As any other local anaesthetic drug, it blocks conduction of nerve impulses. 
Toxicity: 
 It is relatively free of side effects, if it is administered in an appropriate 
dosage and in the correct anatomic location. 
 Systemic toxicity reactions primarily involve CNS and CVS.  The blood 
level required to produce CNS toxicity is less than that required of circulatory 
collapse. 
CNS toxicity: 
Initial symptoms include feeling of light headedness and dizziness, 
followed by visual and auditory disturbances.  Objective signs are excitatory and 
include shivering, muscle twitching and tremors.  Ultimately, generalized tonic 
clonic seizures can occur.  The typical plasma concentration of levobupivacaine 
associated with seizures is lesser than that of bupivacaine. (levobupivacaine 
103mg vs 85 mg bupivacine). 
CVS toxicity: 
There is lesser affinity and strength of inhibitory effect of levobupivacaine 
on cardiac sodium channel than bupivacine.it causes lesser depressant
 effect on AV conduction, QRS duration and lesser impairment of 
contarctile function on heart based on animal studies, sodium and pottasium 
channels blocked in lesser potent than bupivacaine. 
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Neurotoxicity: 
 Placement of levobupivacaine into epidural space can cause neurotoxicity.  
Whose spectrum may range from patchy groin numbness and persistent isolated 
myotomal weakness to cauda equine syndrome. 
Availability 
Chirocaine is a sterile, non-pyrogenic, colorless solution (pH 4.0-6.5) 
containing levobupivacaine hydrochloride equivalent to 2.5 mg/mL, 5.0 mg/mL, 
and 7.5 mg/mL of levobupivacaine, sodium chloride for isotonicity, and Water for 
Injection. Sodium hydroxide and/or hydrochloric acid may have been added to 
adjust pH. Chirocaine is preservative free and is available in 10 mL and 30 mL 
single dose vials. 
Dosage 
 Maximal dose is 2mg/kg body weight for epidural and nerve/ plexus 
blockade.  For subarachnoid block maximum dose is 20mg (4cc 0.5%). 
Route, onset time and duration. 
Route Onset (Mins.) Duration (Mins.) Concentration (%) 
Intrathecal 5 90 – 200 0.5 (or) 0.75 
Epidural 15-20 180-350 0.25 (or) 0.75 
  
CLINICAL APPLICATIONS : 
Subarchanoid block : 
 Levobupivacine produces similar sensory, motor and recovery parameters 
like bupivacaine, intrathecal administration of 11.5mg produces adequate sensory 
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and motor block for 6.5 hrs ,(5-10 mg) in a smaller dose used in day care surgeries 
.The minimum effective dose is 11.7 mg. 
EPIDURAL ANESTHESIA: 
        Levobupivacaine and bupivacaine in equal dose (15ml) of 0.5% produces 
similar onset of sensory (8-30 min), maximum cephalic spread (T7-T8) and 
duration of analgesia for 4-6 hrs. Concentrations like 0.75 % vs 0.5% provides 
longer sensory and motor duration without any increase in incidence of adverse 
effects. 
Continuous infusion of 15 mg/h of levobupivacaine provides effective pain 
relief in post-op period and in cesarean section under epidural anesthesia incidence 
of hypotension is similar for both levobupivacaine and bupivacaine. 
WOUND INFILTRATION: 
Levobupivacaine 0.125% in wound and post incisional infiltration of 
produces more effective and longer duration of analgesia and early mobilisation. 
it has positive effect on wound healing and  but negative effect on wound tension 
by decreasing it. 
PERIPHERAL NERVE BLOCK: 
Epinephrine with levobupivacaine reduces the systemic toxicity, but it does 
not prolong duration of sensory and motor block. 
 levobupivacaine with clonidine and fentanyl produces good analgesia and local 
anesthetic sparing effect and also decreases post op morphine requirement. 
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EPIDURAL LABOR ANALGESIA : 
Levobupivacaine produces less motor block and less toxicity provide 
adequate and safe labor analgesia with no effect duration of labor, mode of 
delivery and neonatal outcome.  
Epidural dose for labor analgesia 0.125% infusion of 125 mg/hr or 0.25% up to 
25mg/r at 15 min intervals. 
OPTHALMIC SURGERY: 
Levobupivacaine in 0.75%   used in various ocular blocks including 
peribulbar block for cataract surgery and retro bulbar block for vitreo-retinal 
surgery because of its  lower cardiovascular and neurological toxicity . 
PEDIATRIC ANESTHESIA: 
Subarachanoid block dose is 1.2 g/kg of isobaric 0.5% levobupivacaine. 
Caudal block dose is 2.5mg/kg. 
GERIATRIC ANESTHESIA:  
levobupivacaine is considered to be a better local anesthetic than 
bupivacaine in the geriatric patient with co-morbid systemic diseases    because of 
its better  pharmacologic profile . 
ADVERSE REACTIONS: 
Nausea, Vomiting, Headache, Hypotension, Dizziness, Procedural pain 
CONTRAINDICATION: 
Intravenous regional anesthesia, Allergy for LA 
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REVIEW OF LITERATURE 
"Gulen guler et al1  2012, conducted a study to investigate the clinical 
efficacy of levobupivacaine and bupivacaine for spinal anesthesia in cesarean 
section,   Group L recieved 10 mg levobupivacaine  with fentanyl 15 mcg and 
Group B received 10mg bupivacaine with fentanyl 15 mcg. They observed in 
group B motor block was faster and longer, bradycardia, hypotension and nausea 
less in group L". 
  "Bremerich DH  et  al2  carried  out  a  dose  finding  investigation  of 
levobupivacaine for parturient undergoing elective caesarean delivery in 
2007.Parturients received either 7.5, 10 or 12.5 mg intrathecal hyperbaric 0.5% 
levobupivacaine,they recommended 10 mg levobupivacaine for parturients 
undergoing elective caesarean section with spinal anaesthesia". 
A study carried out by Camorcia et al3 in 2007, compared the relative 
potencies of intrathecal ropivacaine, levobupivacaine and bupivacaine for motor 
block.They concluded that potency for motor block when administered via 
intrathecal route was low for ropivacaine, intermediate for levobupivacaine and 
high for bupivacaine. 
Aygen Turkmenin et al4, conducted a prospective study, 50 gravidas, who 
were scheduled for cesarean section .They were randomized into group A 7.5 mg 
0.5% bupivacaine with 15 µg fentanyl intrathecally; Group L levobupivacaine 7.5 
mg of 0.5% levobupivacaine with 15 µg fentanyl intrathecally, the level of sensory 
and motor blocks were tested by pin-prick test and bromage scale, respectively. 
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 Results: the time to sensory block at the t4 dermatome was shorter in group b 
(group b, 4.8 min; group l, 6.0 min; p <0.05). The time to maximum motor block 
was also shorter in group b (group b, 3.4 min; group l, 4.7 min; ). The duration of 
analgesia in group L was longer compared to group B (group b, 102 min; group l, 
118 min; p <0.05).  
"In bupivacaine + fentanyl group, time to sensory and maximum motor 
block was shorter and   duration of analgesia was longer in the levobupivacaine + 
fentanyl group. Although levobupivacaine is a novel drug, it is a good alternative 
for bupivacaine". 
"Filiz Karaca et al5, conducted a study in 30 pregnant women for cesarean 
section, Group C received intrathecal isobaric 7.5 mg 0.5% levobupivacaine (1.5 
ml) and 20 µg fentanyl (0.4 mL), while the ones in Group B had intrathecal 
isobaric 7.5 mg 0.5% bupivacaine (1.5 mL) and 20 µg fentanyl (0.4 mL). 
Following spinal anesthesia, hemodynamic parameters, onset and recovery time 
of sensorial and motor block, side effects, Apgar scores of the newborns, blood 
gas levels of the umblical artery, pain scores (VAS) of the patients, surgeon, 
patient and anesthesiologist satisfaction were recorded.  They found that the 
addition of 20 µg of fentanyl in low doses of intrathecal 7.5 mg of 0.5% isobaric 
levobupivacaine and 7.5 mg of 0.5% isobaric bupivacaine in elective caesarean 
section operations provided sufficient analgesia for surgery, and this had no 
negative effect on the mother or the baby. levobupivacaine + fentanyl can be an 
alternative to bupivacaine + fentanyl in caesarean section operations because the 
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first analgesia is required at a later stage, motor blockade disappears earlier and 
early mobilization is ensured".  
Dilek Subaşı et al6, conducted a study on eighty patients for elective 
cesarean section. In Group BF received 7.5 mg hyperbaric bupivacaine with 25 
mcg fentanyl in Group LF received 7.5 mg hyperbaric levobupivacaine with 25 
mcg fentanyl.  
Results: Group BF hemodynamic parameters such as 45th min MAP was 
lower and motor block level was found to be higher. In Group LF, max sensorial 
block level and postoperative VAS scores were higher.  Onset of motor block time, 
time to max motor block, time to T4 sensorial block, reversal of two dermatome, 
first analgesic need were similar in both groups. They concluded that 
levobupivcaine produces less effective motor blockade and maintains stable 
hemodynamics. 
"In a study by Bremerich et al2. involving 60 patients for caesarean section 
and were administered 0.5% levobupivacaine (10 mg) and 0.5% bupivacaine (10 
mg) in combination with opioid (10 and 20 μg of fentanyl and 5 μg of sufentanil), 
the duration of motor block was found to be shorter in levobupivacaine than 
bupivacaine". 
" Bremerich et al2opined that if additives are not added, Levobupivacaine 
10 mg is recommended for caesarean section with spinal anaesthesia (7.5 mg/ 10 
mg/ 12.5 mg). He also noted that Levobupivacaine showed significantly shorter 
and less pronounced motor blockade when compared to Bupivacaine". 
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Goyal et al7 conducted a study on  30 parturient for elective cesarean 
section .They were  divided in to  Group BF receiving 10 mg  bupivacaine and 25 
mcg fentanyl, or Group LF receiving 10 mg  isobaric levobupivacaine and 25 mcg  
fentanyl.  Hemodynamics like MAP was lower in group BF and in Group LF max 
sensorial block level and postoperative visual analog scale scores were higher. 
“Onset of motor block time, time to max motor block, time to T10 sensorial 
block, reversal of two dermatome, the first analgesic need were similar in both 
groups" 
They concluded that isobaric levobupivacaine is good alternative for 
cesarean section as it provides less motor block and maintains hemodynamic 
stability. 
"Camorcia et al3. reported that intrathecal 0.5 % levobupivacaine had 
weaker motor block potency than 0.5 % bupivacaine in elective cesarean cases 
with CSE anesthesia technique ". 
Erkan yavuz akcaboy et al8 2011 conducted a study Forty nine 
patients scheduled for transurethral prostate surgery. 
              "To evaluate the block quality and clinical effectiveness of low dose 
levobupivacaine, and compare it with low dose bupivacaine when they are 
combined with fentanyl.  Patients in levobupivacaine Group received 5 mg 
levobupivacaine with 25 mcg fentanyl and bupivacaine Group received 5 mg 
bupivacaine with 25 µg fentanyl. Hemodynamic parameters and sensory block 
characteristics were comparable, stable and effective in both groups. 
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They conclude that 5 mg levobupivacaine with 25 mcg fentanyl for 
TURP provides stable hemodynamic profile, patient and surgeon satisfaction 
and effective sensorial blockade with less motor blockade in spinal 
anaesthesia and it is an alternative to bupivacaine". 
"Lee YY et al9, 2005 conducted a study to compare the hemodynamic 
effects, clinical efficacy, motor block of using 2.6 mL of 0.5% 
levobupivacaine  and 2.3 mL of 0.5% levobupivacaine with fentanyl 15 mcg 
in 0.3 mL  in urological surgery". 
 "The hemodynamic changes, and quality of sensory and motor block 
was not significant, they conclude that 2.3 mL of 0.5% levobupivacaine with 
fentanyl 15 microg is as effective as 2.6 mL of 0.5% levobupivacaine alone 
in spinal anaesthesia for urological surgery".  
"Glaser et al10 2002 performed this prospective randomized double 
blinded study to evaluate the anesthetic potencies and hemodynamics of 
intrathecal levobupivacaine compared with racemic bupivacaine". (Eighty 
patients undergoing elective hip replacement received either 3.5 mL 
levobupivacaine 0.5% isobaric or 3.5 mL bupivacaine 0.5% isobaric).   
"The onset time and the duration of sensory and motor blockade 
between groups was not significant (11 +/- 6 versus 13 +/- 8 min; 10 +/- 7 
versus 9 +/- 7 min; 228 +/- 77 versus 237 +/- 88 min; 280 +/- 84 versus 284 
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+/- 80 min). They conclude that levobupivacaine is equal in efficacy but less 
toxic than bupivacaine".  
"NK Girgin et al11 2012 conducted a study to investigate whether the 
addition of 25 µg intrathecal fentanyl to levobupivacaine spinal anaesthesia 
for outpatient inguinal herniorrhaphy allows a subanaesthetic 
levobupivacaine dose to be used". Forty patients were assigned to receive 5 
mg levobupivacaine 0.5% mixed with 25 µg fentanyl (group LF) or 7.5 mg 
levobupivacaine 0.5% (group L). 
 "The highest sensory block levels achieved were T7 (range T5 – T9) 
and T6 (range T4 – T9) in groups LF and L, respectively".   
"The times to two-segment regression, S2 regression, ambulation, 
urination and discharge were all significantly shorter in group LF than group 
L. These results indicate that, for outpatient inguinal herniorrhaphy, 
intrathecal fentanyl combined with low-dose levobupivacaine provides good 
quality spinal anaesthesia and minimizes the need for intra-operative 
analgesia. This protocol is well suited for the outpatient setting because it 
features rapid recovery of full motor power, sensory function and bladder 
function".  
"Opas vanna et al12 2006 conducted a study on  patients undergoing 
elective transurethral endoscopic surgery to investigate the clinical efficacy 
and safety of isobaric solution of levobupivacaine compared with hyperbaric 
48 
 
solution of racemic bupivacaine in spinal anesthesia received either 0.5% 
isobaric levobupivacaine or 0.5% hyperbaric bupivacaine" .  "They concluded 
that both levobupivacaine and bupivacaine showed equal effective potencies 
for spinal anesthesia, regard to both the onset time and duration of sensory 
blockade". 
Mantouvalou et al13 2008 performed study to compare the anesthetic 
efficacy and safety of three local anesthetic agents: racemic bupivacaine and its 
two isomers: ropivacaine and levobupivacaine, in patients undergoing lower 
abdominal surgery. One hundred-twenty patients, ASA I-III, were randomized to 
receive an intrathecal injection of one of three local anesthetic solutions. Group A 
(n = 40) received 3 ml of isobaric bupivacaine 5 mg/ml (15 mg). Group B (n = 40) 
received 3 ml of isobaric ropivacaine 5 mg/ml (15 mg). Group C (n = 40) received 
3 ml of isobaric levobupivacaine 5 mg/ml (15 mg).   
"The onset and duration of sensory block at dermatome level T8, maximum 
upper spread of sensory block, time for 2-segment regression of sensory block as 
well as the onset, intensity and duration of motor block were recorded, as were any 
adverse effects, such as bradycardia, hypotension, hypoxia, tremor, nausea and/or 
vomiting".  
“The onset of motor block was significantly faster in the bupivacaine 
group compared with that in the ropivacaine group and almost the same of 
that in the levobupivacaine group".   
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"Ropivacaine presented a shorter duration of both motor and sensory block than 
bupivacaine and levobupivacaine,Bupivacaine required more often the use of a 
vasoactive drug (ephedrine) compared to both ropivacaine and levobupivacaine 
and of a sympathomimetic drug (atropine) compared to the ropivacaine group".  
Titti et al14  reported that in cesarean section incidence of hypotension 
is 62 percent when they administered 2.5 ml of bupivacaine. 
Fattorni et al15 conducted study on eighty patient who has been posted 
for major orthopedic surgery .there is no significant  characteristic difference 
in sensory and motor block between the levobupivacaine and bupivacaine .In 
levobupivacaine group no incidence of severe hypotension  and cardiovascular 
stability was maintained. 
Parpaglioni et16 all reported that incidence of hypotension is less in 
levobupivacaine compared to bupivacaine and Glasser et al compared that in 
levobupivacaine group causes less incidence of bradycardia and it reduces 
arterial pressure less compared to bupivacaine. 
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MATERIALS AND METHODS: 
 
SOURCE OF DATA   
 After obtaining ethical committee approval from Tirunelveli Medical 
College, 60 Pregnant women of physical status American society of 
anaesthesiologists (ASA) I and II between the age group of 18-35 posted for 
elective lower segment cesarean section at TIRUNELVELI MEDICAL 
COLLEGE HOSPITAL have been selected for the study.  The patients were 
randomly allocated into two groups comprising of 30 patients in each group. 
METHOD OF COLLECTION OF DATA 
Inclusion Criteria 
• ASA physical status I and II,  
• Age between 18-35 years 
• At Term, Elective cesarean Section 
• Valid informed consent  
• Pregnant women with the height ranging between 150 – 170 cms 
• Pregnant women with the weight ranging between 50 – 90 kg. 
Exclusion Criteria 
• Pregnant patients having coexisting systemic disorders like neuromuscular 
diseases, neuronal degenerative disorder, seizure disorder, bleeding and 
hematological disorders, Cardiac disorders, Diabetes mellitus or gestational 
diabetes. 
• Pregnant women with hepatic and renal disorders, severe Anaemia  
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• Eclampsia, placenta previa,abruptio placenta 
• Parturient in active labour, Twin/ complicated pregnancy 
• Spinal deformities, poliomyelitis short stature <145cm 
• Weight less than 50 kgs and more than 90 kgs 
• Patient refusal, Contra – indications to spinal anaesthesic, Allergy to local 
Anesthetic drugs.   
• Fetal distress. 
• Mentally retarded. 
METHODS: 
  Each patients was reassured, explained the procedure and informed 
consent taken.  All patients were confirmed to be physically fit.  Minimal fasting 
period is 8 hrs,following application of routine monitors(NIBP,ECG,PULSE 
OXIMETRY), IV line secured with 18G venflon are given aspiration prophylaxis 
comprising of injection metaclopramide (10mg) and ranitidine (50mg)  IV 10 min 
before surgery & preloaded with RL 10 – 12 ml/ kg . Baseline mean arterial BP 
and pulse rate, Spo2 were noted. Subarachnoid block (SAB) is instituted at L3 – 
L4 or L4-L5 intervertebral space in right Lateral position using 25-G quincke’s 
needle. 
Using a sealed envelope technique,patients were equally and randomly 
divided into two groups. 
         Group L (n = 30); 10 mg 0.5% (2 ml) levobupivacaine  
        Group B (n = 30); 10 mg 0.5% (2 ml) bupivacaine  
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Patients were turned to a 15˚ - 20˚ left lateral supine position. Oxygen 6 L/min was 
administered via a facial mask. Patients were treated with titrated doses of 
• Inj : Ephedrine 6mg I.V. if systolic BP <90mm/Hg or <20% baseline. 
• InJ : Atropine 0.6mg I.V. if Heart  Rate <50/min 
After delivery of baby Inj. Oxytocin 10 IU in drip & 10 IU Im given. 
The sensory level of spinal anesthesia was assessed by pinprick in axillary line 
using a 26 G needle, and was recorded at baseline prior to spinal injection, then 
every 2 minute for the first 15 min after injection, and every five minutes for the 
next 30 min, and at 45 min. 
Blood pressure, heart rate, and the extent of motor block were recorded every 
2 min for first 15 min ,and 5 min for next 30 min and at 45 min.  
Once a T4-T6 level has been reached permission to perform operation given. 
 Parameters to be evaluated 
Sensory: 
• Time for onset of  sensory block by pinprick 
• The time taken to reach peak sensory block level 
• The time to regression of two dermatomes of the sensory block 
Sensory score: 
Score Response 
0 normal sensation 
1 analgesia (loss of pin prick sensation) 
2 anesthesia (loss of touch sensation) 
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Motor 
• Time of onset of motor block 
• Time to maximum motor block level 
• Degree of motor block (as per Bromage scale) 
• Total duration of motor block 
  Motor block was assessed with modified Bromage scale  
Grade Response Degree of block 
0 no motor block  Nil (0%) 
1 unable to straight leg raise Partial (33%) 
2 unable to flex knee against resistance Almost complete (66%) 
3 unable to flex ankle complete 
 
The time to onset of motor block, the time to reach Bromage 3 and the time 
of complete disappear ance were recorded.  
SENSORY BLOCK ONSET TIME 
Time interval between end of anesthetic injection and appearance of 
cutaneous analgesia in dermatomes assessed by the pin prick test T-12, T-10, T-8, 
T-6. 
DURATION OF MOTOR BLOCK 
Administration of anesthetic and attainment of grade 0 in Bromage motor 
scale. 
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TIME FOR TWO SEGMENT REGRESSION: 
The duration of two segment regression was defined as the time taken for 
the sensory block to regress from the maximum level of blockade to two segment 
down. 
DURATION OF ANALGESIA 
Administration of anesthetic agent and disappearance of cutaneous level of 
sensation at each dermatomal level. 
POST-OP ANALGESIA DURATION 
Administration of anesthetic drug and time of analgesic requirement in 
PACU. 
The occurrence of Adverse events including Bradycardia, Hypotension, 
decrease in oxygen saturation SP02 < 93 %, shivering, Nausea and vomiting were 
also recorded. 
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OBSERVATION AND RESULTS 
All 60 patients in two groups completed the study without any exclusion. 
We did an inter group analysis and the results were as followed. Of the 60 patients 
30 belonged to Group B (Hyperbaric Bupivacaine) and other 30 categorized as 
Group L (Isobaric Levobupivacaine). Data were presented as range, mean, 
standard deviation. The probability value ‘P’ of less than 0.05 considered 
statistically significant.  
Age, weight , height of the patient between both the groups were 
comparable and were not statistically significant (P>0.05)  
Table – 1 Comparison of Age (yrs),Wt(kg), Height(cm) Distribution between 
the two groups 
PARAMET
R  
GROU
P  
FREQUENC
Y  
MEA
N  
STANDAR
D  
DEVIATIO
N  
p  
VALU
E   
‘t’ 
TEST 
AGE  B 30  25.90 9.87 0.419  
L 30  24.36 2.99 
WEIGHT  B  30  71.00  6.41 0.779 
L 30  71.43 5.45  
HEIGHT  B  30  159.1
0 
6.445  0.161 
L 30  160.1
0 
6.922  
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CHART – 1 Comparison of Age (yrs) Distribution between the two 
groups  
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85%
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<20 years 21 to 30 years >31 years
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CHART – 2 Comparison of Weight (kg) distribution between the two groups  
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CHART – 3  Comparison of height (cm) distribution between the two groups  
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Table 2:   Comparison of duration of surgery (min)  between the two groups  
 
  
 
The average duration of surgery in both groups was comparable the "P " 
value of 0.563 which was not significant. 
 
 
     
  
 
Parameter  
Duration of Surgery ( in minutes)  
Group B  Group L  
Range  45-60 50-60 
Mean  52.10 52.73 
SD  4.11 4.32 
‘p’  0.563 
Not significant  
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CHART – 4 Comparison of duration of surgery (min) between the two groups  
 
52.10
52.73
42.00
44.00
46.00
48.00
50.00
52.00
54.00
56.00
58.00
Bupivacaine Levobupivacaine
Duration of surgery (min)
 
 
 
 
 
 
 
 
 
            
  
61 
 
Table - 3 Comparison of PR between two groups at various intervals.  
 
PULSE  
RATE  
GROUP  FREQUENCY  MEAN  STANDARD 
DEVIATION  
p  
VALUE   
‘t’  
TEST  
BASELINE  
B 30  93.33 8.59 .512  
  L  30  83.76  7.7  
2 MIN  
B 30  86.4 9.82  
.475  
L 30  84.73  8.04  
5 MIN  
B  30  77.7 11.46  .067 
  L 30  83.66  8.74 
10 MIN  
B  30  84.33 9.81 .542 
  L  30  80.1 5.89  
15 MIN  
B 30  89.16 7.68  .088 
  L  30  84.66 6.69 
30 MIN  
B  30  88.43 8.81   
.265  L 30 83.03 6.68  
45 MIN  
B 30 94.93 9.06 
.124  
L 3 0 83.76 7.7  
 
  Table 3 shows distribution of pulse rate at various intervals between two 
groups and p value is statistically insignificant. 
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     CHART – 5   Comparison of Pulse Rate (min) between the two groups  
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Table - 4 Comparison of MAP between two groups at various intervals.  
MAP GROUP  FREQUENCY  MEAN  STANDARD 
DEVIATION  
p  
VALUE   
‘t’  
TEST  
BASELINE  
B 30  85.78 5.34 .356 
  L  30  87.1  7.24 
2 MIN  
B 30  90.06 6.09  
.0258 
L 30  88.26 6.11  
5 MIN  
B  30  70.56 9  .0001 
  L 30  87.53  10.23 
10 MIN  
B  30  68.4 6.47 .0001 
  L  30  84.1 7.35  
15 MIN  
B 30  69.4 5.72  .0001 
  L  30  84.53 6.72 
30 MIN  
B  30  71.7 6.22   
.0001  L 30 83.46 4.5 
45 MIN  
B 
30 74.76 
 
4.68 
.0001  
L 30 86.66 3.53  
  
Table 4 shows the distribution of hemodynamic variables at various interval 
between the two groups and p value is statistically significant 
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   CHART – 6 Comparison of Mean Arterial Pressure (mmhg) between the 
two groups  
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 Table - 5 Comparison of Spo2 between two groups at various intervals.  
 
PULSE  
RATE  
GROUP  FREQUENCY  MEAN  STANDARD 
DEVIATION  
p  
VALUE   
‘t’  
TEST  
BASELINE  
B 30  99.03 1.84 .428 
  L  30  99.36  1.35 
2 MIN  
B 30  100 0 
N/A  
L 30  100  0 
5 MIN  
B  30  100 0 N/A 
  L 30  100 0 
10 MIN  
B  30  99.16 0.94 .425 
  L  30  99.4 1.27  
15 MIN  
B 30  99.8 0.48  .577  
  L  30  99.86 0.43 
30 MIN  
B  30  99.73 0.44   
.177 L 30 99.5 0.82 
45 MIN  
B 30 99.83 0.46  
.074  
L 3 0 99.53 0.77 
 
The Table 5 shows distribution of spo2 at various interval between two groups 
which is statistically insignificant. 
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   CHART – 7 Comparison of SPO2 between the two groups at various   
intervals 
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Table 6:   Comparison of time of onset of sensory block (min) between the two 
groups  
  Time of onset of sensory block  
Parameter  (in minutes)  
Group B  Group L  
Range  1-3  1-2  
Mean  1.83 2.03 
SD  0.37  1.73669  
‘p’ value  <0. 082 
not Significant  
   
The table 6 shows time of onset of sensory block which was not statistically 
significant between two groups. 
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CHART – 8    :   Comparison of time of onset of sensory block (min) between 
the two groups 
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Table 7:   Comparison of time to reach maximum sensory level (min) between 
the two groups  
  
  Time to reach maximum sensory level  
Parameter  (in minutes)  
Group B  Group L  
Range  9-20 8-15  
Mean  13.46 11.43 
SD  1.47 1.75  
‘p’ value  <0. 0001  
Significant  
  
In table 7 time to reach maximum sensory block in the two groups were 
depicted. P value is statistically significant. The time to reach maximum 
sensory block was faster in Group L (11.96 ± 1.97) when compared with 
Group B (13.16 ± 2.57).  
70 
 
CHART – 9    Comparison of time to reach maximum sensory level (min) 
between the two groups  
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Table 8 :   Comparison of peak level of  sensory block (min)  between the two 
groups    
  
Peak level of  
Sensory Block  
Number of cases in  
Group B  Group L  
No.  %  No.  %  
T2  6 20% 2 7% 
T4  12 40% 8 27% 
T6  12 40% 20 66% 
Total  30  100% 30  100 % 
 
 
In this table the distribution of level of sensory block in both groups were 
given.  T6, the ideal peak sensory level is attained.  
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CHART – 10    Comparison of maximum  sensory level between the 
two groups . 
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Table 9 :   Comparison of time to two sement regression (min)  between the 
two groups  
 Time to two segment regression  
  
Parameter  
( in minutes)  
    
 Group B  Group L  
Range  70-80  60-70  
Mean  74.53  65.17 
SD  3.501  3.291  
‘p’ value  <0. 0001  
Significant  
  
Table shows the distribution of time to two segment regression between 
the two groups.  In Group B the time to two segment regression was prolonged 
(75.13 ±3.501) when compared with Group L (65.17± 3.29) and it is 
statistically significant. 
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   CHART – 11    Comparison of time to two sement regression (min)  between 
the two groups  
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Table 10 :   Comparison of time of onset of motor block (min)  between the 
two groups  
  Time of onset of motor level  
Parameter  (in minutes)  
Group B  Group L  
Range  2-4 2-6 
Mean  2.93 4.51 
SD  0.52 0.87  
‘p’ value  <0. 0001  
Significant  
 
Table 10 shows the time of onset of motor block between groups ,onset of motor 
block is faster in Group B(2.36±0.61)when compared with Group L(4.1±0.88) P 
value is statistically significant. 
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CHART – 12   Comparison of time of onset of motor block (min)  between 
the two groups  
            
2.93
4.51
0
1
2
3
4
5
6
Bupivacaine Levobupivacaine
Time to onset of motor block(min)
 
 
 
 
 
 
 
 
 
 
 
  
77 
 
Table 11  :   Comparison of time to maximum motor block level between two 
groups 
  Time to maximum motor block level 
Parameter   
Group B  Group L  
Range  4-10 5-15 
Mean  6.43 11.66 
SD  1.13 2.12 
‘p’ value  <0. 0001  
Significant  
 
In table time to reach maximum motor block in the two groups were 
depicted. P value is statistically significant .The time to reach maximum motor 
block was faster in Group B ( 6.13 ± 0.67)  when compared with  Group L 
(11.6 ± 2.35). 
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CHART – 13 Comparison of time to maximum motor block level between 
two groups 
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Table 12  :   Comparison of duration of  motor block level between two groups 
 
  duration of  motor block level 
Parameter   
Group B  Group L  
Range  125-155 90-115 
Mean  135.03 101.06 
SD  4.81 9.42 
‘p’ value  <0. 0001  
Significant  
 
In table duration of   motor block in the two groups were depicted. P value is 
statistically significant .The duration of motor block was prolonged in Group B 
(132.66 ± 7.15) when compared with Group L (99 ± 9.13).  
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CHART – 14    Comparison of duration of  motor block level between two 
groups 
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Table 13  :   Comparison of Adverse effects between two groups 
 
  
Adverse effects  Group B  Group L  
No  %  No  %  
Hypotension  7  23  2  7  
Bradycardia  2  7  1  3  
Shivering  2  7  2  7  
Vomiting  1  3  2  7  
Total cases with adverse      
effects  12*  40  7*  23  
Total cases without adverse      
effects  18*  60  23*  77  
Total  30*  100  30*  100  
  
* More than one adverse effect was present in one case in each Group Adverse 
effects between the two groups were comparable.   
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CHART – 15     Comparison of Adverse effects between two groups 
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DISCUSSION 
 
            Spinal anesthesia, providing an effective surgical anesthesia and 
postoperative analgesia by ensuring minimal maternal and neonatal side effects, 
has been reported to be more advantageous than general anesthesia for caesarean 
operations. 
Bupivacaine is a preferred agent in obstetric anesthesia due to its long 
lasting action and lower levels of placental transition; most serious side effect is 
cardiotoxicity, which makes pregnant women, more sensitive to this effect.          
       Levobupivacaine is a more favorable local anesthetic agent in 
terms of safety profile with similar pharmacokinetic properties to racemic 
bupivacaine. However, trials have reported that the cardiovascular and central 
nervous system-related side effects of levobupivacaine are less than those of 
bupivacaine, though the onset and duration of action, hemodynamic changes 
after spinal anesthesia are the same for levobupivacaine and bupivacaine.  
We conducted a randomized, double-blind, case-control study to evaluate 
the hemodynamic stability of intrathecal Isobaric Levobupivacaine 10mg for 
cesaerean which was based on of  Gulen guler et al1 2012, conducted a study to 
investigate the clinical efficacy of levobupivacaine and bupivacaine for spinal 
anesthesia in cesarean section.   Group L recieved 10 mg levobupivacaine with 
fentanyl 15 mcg and Group B received 10mg bupivacaine with fentanyl 15 mcg. 
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They observed in group B motor block was faster and longer, bradycardia, 
hypotension and nausea less in group L Bremerich DH2 et al carried out a dose 
finding investigation of levobupivacaine for parturients undergoing elective 
caesarean delivery in 2007.Parturients received either 7.5, 10 or 12.5 mg 
intrathecal hyperbaric 0.5% levobupivacaine. They recommended 10 mg 
levobupivacaine for parturients undergoing elective caesarean section with spinal 
anaesthesia. 
"In our study, sensory block levels required for cesarean section were 
achieved in both groups, and it was observed that the hemodynamic stability with 
levobupivacaine was better maintained". 
Goyal et al7 conducted a study on  30 parturient for elective cesarean section 
.They were  divided in to  Group BF receiving 10 mg  bupivacaine and 25 mcg 
fentanyl, or Group LF receiving 10 mg  isobaric levobupivacaine and 25 mcg  
fentanyl.  Hemodynamics like MAP was lower in gruop BF and in Group LF max 
sensorial block level and postoperative visual analog scale scores were higher. 
“Onset of motor block time, time to max motor block, time to T10 sensorial block, 
reversal of two dermatome, the first analgesic need were similar in both groups" 
They concluded that isobaric levobupivacaine is good alternative for cesarean 
section as it provides less motor block and maintains hemodynamics stability. 
            In our study we observed that maximum sensory block level in 
bupivacaine group was higher and development of motor block was faster and 
lasted longer. 
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      “The results of our study are similar to  Gautier et al17   reported during 
spinal anesthesia for cesarean delivery, they compared the same doses of 
levobupivacaine and bupivacaine, and reported that while adequate anesthesia 
was maintained in the 97% of the patients in the bupivacaine group, this rate 
was 80% in the levobupivacaine group, and duration of motor block and 
analgesia was shorter in the levobupivacaine". 
In a study by bremerich et al2.10 involving 60 patients who were 
scheduled for caesarean section and were administered 0.5% levobupivacaine 
(10 mg) and 0.5% bupivacaine (10 mg) in combination with opioid (10 and 
20 μg of fentanyl and 5 μg of sufentanil), the duration of motor block was 
found to be shorter with levobupivacaine compared to bupivacaine. 
In a study by Copperjans et al18. comparing 6.6 mg of bupivacaine 
supplemented with 3.3 µg of sufentanil, 6.6 mg of levobupivacaine and 10 
mg of ropivacaine, they found a better value of systolic blood pressure in the 
levobupivacaine group. 
In our study, we used 10mg of 0.5 % Hyperbaric bupivacaine for 
intrathecal injection. We measured the time of onset and duration of sensory 
block, hemodynamic changes, modified bromage scale, duration of motor 
block and adverse effects all these were measured from the time of injection 
of subarachnoid block.  
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In our study, we found that both Isobaric Levobupivacaine and 
Hyperbaric bupivacaine produces equal efficacy of motor and sensory 
blockade. Isobaric levobupivacaine produces effects with minimal adverse 
effect which is similar to randomized double blind study conducted by Glaser 
et al10.   
Mantouvalou et al13  performed a study to compare three local 
anesthetic agents: racemic bupivacaine and its two isomers: ropivacaine and 
levobupivacaine, for  anesthetic efficacy and safety  in patients undergoing 
lower abdominal surgery. They found that levobupivacaine required less 
vasoactive drugs with equal efficacy of motor and sensory blockage.  In our 
study hypotension is more prevalent in Hyperbaric bupivacaine than isobaric 
levobupivacaine.In our study we found that the time to two segment 
regression is earlier in Isobaric levobupivacaine than hyperbaric bupivacaine 
which is supported by NK Girgin et al11 2012.  
In our study we found that the potency of two drugs, duration of motor block is 
higher in Hyperbaric bupivacaine (Range 125-155min,) than Isobaric bupivacaine 
(Range 90-115min).    
A study carried out by Camorcia et al3 in 2007 compared the relative 
potencies of intrathecal ropivacaine, levobupivacaine and bupivacaine for 
motor block.They concluded that potency for motor block when administered 
via intrathecal route was low for ropivacaine, intermediate for 
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levobupivacaine and high for bupivacaine,which is in keeping with our 
findings. 
Fattorni et al15 conducted study on eighty patient who has been posted 
for major orthopedic surgery .there is no significant  characteristic difference 
in sensory and motor block between the levobupivacaine and bupvacaine .In 
levobupivacaine group no incidence of severe hypotension   and 
cardiovascular stability was maintained. 
Glasser et al10 compared that in levobupivacaine group causes less 
incidence of bradycardia and it reduces arterial pressure less compared to 
bupivacaine. 
In my study, we found that occurence of bradycardia is mor prevalent 
in Group B bupivacaine 0.5 % than Group L isobaric levobupivacaine 0.5%   
. This findings has been supported by Mantouvalou et al13  performed  study  
which compared to both ropivacaine and levobupivacaine , Bupivacaine 
required more often the use of ephedrine and atropine. 
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SUMMARY 
Sixty term pregnant women of A S A I and II physical status who 
presented for elective caesarean section were included in this double blinded 
study. 
 They were randomly and equally allotted into two groups namely, 
Group B and Group L  
Patients in Group B received 0.5% hyperbaric bupivacaine 10mg intrathecally.  
Patients in Group L received 0.5% Isobaric Levobupivacaine 10mg intrathecally.  
They were observed for  
 
• Onset time for sensory block.  
• The time taken to reach peak sensory block level. 
• Regression time to two dermatomes for sensory block. 
• Onset of motor block. 
• Time for maximum motor block level. 
• Duration of motor block. 
• Hemodynamic changes. 
• Adverse effects.  
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• The collected data was analysed using Student’s’ test and a ‘p’ value <0.05 
was considered significant.  
 
Group L showed a better hemodynamic stability in terms of mean 
arterial pressure and there was no significant difference in terms of pulse rate 
between the two groups.  
 Patients in bupivacaine group had a faster onset of sensory block, 
Group B patients showed significantly longer duration of sensory analgesia 
and motor block.  
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CONCLUSION 
 
0.5% Isobaric Levobupivacaine 10mg for intrathecal injection of caesarean 
section produces adequate sensory and motor blockade and stable hemodynamic 
parameters with minimum adverse effects than 0.5% hyperbaric bupivacaine 
10mg. We concluded that isobaric levobupivacaine is a better alternative for 
caesarean section. 
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PROFORMA 
Case No: 
Name:  Age: I.P.No. Date: 
Address: 
 
 Unit: Weight: Height: 
Indication:     
Surgeon:     
Pre – Operative status 
Anaemia: Yes / No A.S.A. Grade: 
Pulase Rate: BP: CVS: Rs. 
AIR WAY 
Investigation : HB% 
Urine – Albumin    Sugar   Deposits 
Blood Sugar     Urea   Creatinine 
HIV     VDRL    Hbs Ag,  ECG,    Blood Group 
Pre Medication      
Inj. Ranitidine 50mg   
Inj. Metoclopramide 10mg   
Anaesthetic Technique 
Preloading  : Yes / No   Amount infused 
Position for S.A.B.    Level of Injection : L3 – L4 
No. of attempts:    Needle: 
96 
 
Time of Injection: 
Drug given: 
 
Dose: 
 
Group B :  
Group L :  
 
Group    B(  )/L(  )  
Position and site of injection      
Time of intrathecal injection of drug      
Time of onset of sensory block      
Peak level of sensory block      
Duration of procedure      
Time of two segement regression      
Modified bromage scale      
Duration of Motor blockade      
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Intraoperative hemodynamic changes:  
  0 min  2 min  5 min  10 
min  
15  
min  
30 
min  
45 
min  
1 hr After 
the 
procedure  
HR                  
BP                  
SpO2                  
 
Side effects and complications:  
Insufficient Block     :  
Any discomfort   : Nausea, Vomiting, pruritus, pain  
Hypotension     :  
Bradycardia       :  
Shivering        :  
Post Op. headache and back pain: 
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Muha;r;rp xg;Gjy; gbtk; 
 
 
rpNrhpad; Kiwapy; nra;ag;gLk; KJFj; jz;Ltl ePhpy; Crpapd; %yk; 
cgNahfg;gLj;jf;$ba ,uz;L kaf;f kUe;Jfspd; tpisTfs; gw;wp Ma;T 
 
ngah;    : 
taJ    : 
,dk;    : 
cs;Nehahsp vz;  : 
thh;L    : 
Neha;    : 
mWit rpfpr;ir  : 
 
tpsf;fk; : 
 rpNrhpad; Kiwapy; nra;ag;gLk; mWit rpfpr;irf;fhf kaf;f kUe;jpid 
KJFj; jz;Ltl ePhpy; Crp %yk; nrYj;jp jw;fhypfkhf czh;tpof;f nra;Ak; 
Kiwapy; GgpNtnfa;d; vDk; kUe;J gutyhf cgNahfpf;fg;gLfpd;wJ. ,e;j 
Kiwapy; yPNthGgpNtnfa;d; vDk; Muha;r;rpf;fhd KJFj;jz;Ltl ePhpy; Crp 
%yk; nrYj;jp mWit rpfpr;ir nra;tjdhy; Vw;gLk; gad;fs;> tpisTfs;> gf;f 
tpisTfs; gw;wp vdf;F ed;F Ghpfpd;w jkpo; nkhopapy; njspthf tpsf;fp 
$wg;gl;lJ. 
 vd;Dila milahsk; ve;j tifapYk; ,e;j Muha;r;rp %yk; ntspNa 
njhpahJ vd;gij mwpNtd;. ,e;j Muha;r;rpapy; ,Ue;J ve;j NeuKk; tpyfyhk; 
vd;gijAk; mjdhy; ve;j ghjpg;G Vw;glhJ vd;gijAk; mwpNtd;. 
 ehd; ahUila eph;ge;jKkpd;wp vd; nrhe;j tpUg;gj;jpd; Nghpy; Ra 
epidTld; ,e;j Muha;r;rpapy; gq;F nfhs;s rk;kjpf;fpNwd;. 
 
,lk; : jpUney;Ntyp      ifnahg;gk; 
ehs; : 
 
Baseline
2 Mins 
after SAB
5 Mins 
after SAB
10 Mins 
after SAB
15 Mins 
after SAB
30 Mins 
after SAB
45 Mins 
after SAB
1 ARUMUGAKANI 21 65 156 50 B 88 92 56 98 100 102 98
2 SELVI 27 66 158 55 B 92 96 68 92 88 83 92
3 VIMALA 24 68 158 53 B 102 88 82 88 88 76 102
4 DIVYA 26 80 156 52 B 108 82 88 86 86 88 108
5 UPPIDATHAI 22 72 157 48 B 98 88 78 82 86 96 98
6 VIMALA 23 77 159 59 B 100 98 88 84 87 92 100
7 RENU 26 68 160 52 B 88 92 56 98 102 106 100
8 FATHIMA 19 64 161 50 B 68 100 68 82 90 88 68
9 JAYASHREE 20 83 163 48 B 98 89 88 76 84 94 98
10 GOMATHY 35 75 155 55 B 78 86 88 78 86 96 78
11 MURUGESHWARI 24 66 158 51 B 98 82 54 100 98 100 102
12 SHANTHI 75 82 157 47 B 112 76 86 88 88 86 112
13 RENU 23 79 164 52 B 96 78 72 74 78 88 96
14 REVATHI 20 66 157 49 B 92 74 58 110 106 110 92
15 SHANMUGAKANI 27 79 157 60 B 86 88 78 74 84 82 86
16 MALATHY 25 70 159 56 B 99 82 78 80 86 80 99
17 SRIDEVI 24 66 156 58 B 98 92 88 82 88 78 98
18 MAGESHWARI 23 68 162 54 B 88 96 55 98 106 80 110
19 DHARSHINI 22 82 158 50 B 100 55 86 96 102 100 100
20 SHOBANA 21 74 161 56 B 88 82 82 84 86 84 88
21 VADIVUKARASI 25 67 157 57 B 102 76 86 86 82 80 102
22 ABIRAMI 27 65 161 48 B 89 78 88 88 84 86 89
23 PONMUTHU 20 68 156 59 B 86 92 82 78 88 84 86
24 KALEESHWARI 21 65 161 49 B 92 100 86 78 92 90 92
25 ASHWINI 26 82 163 48 B 96 102 82 68 96 92 96
26 BHARATHI 26 67 157 47 B 88 94 76 76 78 80 88
27 KIRTHIGA DEVI 30 66 159 48 B 92 88 78 70 86 86 92
28 NANDHINI 28 67 160 49 B 98 86 88 80 82 78 98
29 RAJESHWARI 25 65 164 56 B 92 82 82 76 82 80 92
30 SUDHA 22 68 163 47 B 88 78 86 80 86 88 88
31 KRISHNAVENI 27 70 163 56 L 78 76 88 76 88 82 78
32 NIRMALA 27 73 164 48 L 96 68 82 78 86 80 96
33 PARVATHY 21 67 160 47 L 90 76 86 80 82 80 90
34 NIVEDITHA 28 74 157 48 L 80 78 54 88 98 102 80
35 VANDHANA 23 74 159 57 L 82 82 98 90 90 88 82
36 TAMIL SELVI 26 68 163 50 L 72 88 88 92 90 86 72
37 SHANMUGA PRIYA 25 70 162 49 L 76 92 82 88 82 80 76
38 RUBINI 22 73 157 60 L 88 100 86 78 80 78 88
39 FATHIMA FARZANA 29 71 163 49 L 92 86 78 72 76 88 92
40 MARY 22 77 164 56 L 86 82 76 74 78 80 86
41 TAMILARASI 19 65 156 50 L 88 86 78 70 78 80 88
42 MUTHUKUMARI 21 66 157 53 L 82 98 72 76 80 78 82
43 ESAKKIAMMAL 23 68 156 52 L 96 92 78 70 80 74 96
44 LAKSHMI 20 76 159 48 L 88 96 82 78 82 76 88
45 MARIAMMAL 30 65 160 59 L 70 92 86 80 84 70 70
46 KAYATHRI 21 80 163 48 L 68 78 84 83 86 80 68
47 MEERA 23 71 159 55 L 75 76 78 76 88 84 75
48 BACKIYALAKSHMI 20 80 158 59 L 86 72 98 88 88 82 86
49 ESTHER 24 65 157 60 L 72 82 92 86 92 78 72
50 INDHIRA 26 69 164 56 L 86 88 90 76 94 90 86
51 POORNIMA 28 78 162 54 L 82 98 88 82 90 88 82
52 AMUTHAMOZHI 22 65 156 47 L 88 92 78 82 88 84 88
53 ARUNA 26 79 163 48 L 78 76 88 76 72 76 78
54 NATHIYA 28 64 164 49 L 82 78 82 78 74 80 82
55 MALLIKA 22 74 160 53 L 86 86 80 76 78 88 86
56 SATHYA PRIYA 24 82 163 54 L 88 84 90 78 76 86 88
57 POORNAKALA 25 63 159 55 L 82 82 100 88 86 89 82
58 RASI 27 67 158 57 L 98 84 78 86 88 90 98
59 AMBIKA 25 72 159 57 L 90 88 84 78 88 78 90
60 SASIKALA 27 77 158 48 L 88 86 86 80 98 96 88
Sl.No. Name
Age    (in 
yrs)
Weight(i
n kgs)
Height 
(in cms)
Duration 
Surgery 
(MIN)
Pulse Rate
Group
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Sl.No.
Baseline
2 Mins 
after SAB
5 Mins 
after SAB
10 Mins 
after SAB
15 Mins 
after SAB
30 Mins 
after SAB
45 Mins 
after SAB
Baseline
2 Mins 
after SAB
5 Mins 
after SAB
10 Mins 
after SAB
15 Mins 
after SAB
30 Mins 
after SAB
45 Mins 
after SAB
B 72 96 56 58 60 65 70 100 100 100 100 100 100 100
B 76 90 65 66 68 70 76 100 100 100 100 100 100 100
B 68 98 70 68 70 72 76 100 100 100 100 100 100 100
B 82 100 74 70 72 76 76 100 100 100 100 100 100 100
B 74 86 75 70 74 78 76 98 100 100 98 100 99 100
B 72 88 72 70 70 78 76 99 100 100 99 100 100 100
B 76 80 70 75 78 80 82 98 100 100 98 100 100 100
B 78 90 80 76 74 84 80 100 100 100 100 100 100 100
B 90 95 82 78 80 86 78 90 100 100 98 100 99 100
B 72 90 80 76 78 80 80 99 100 100 98 100 100 100
B 77 96 58 60 64 66 70 99 100 100 99 100 100 100
B 81 98 80 72 70 68 76 99 100 100 99 100 100 100
B 82 90 78 74 72 70 74 100 100 100 100 99 99 100
B 70 88 52 56 60 64 70 99 100 100 99 99 100 100
B 81 84 50 55 60 66 70 98 100 100 98 99 100 100
B 70 86 78 80 76 74 78 100 100 100 100 100 99 100
B 78 88 76 70 72 70 78 100 100 100 100 100 100 100
B 86 90 58 56 60 70 74 99 100 100 97 100 100 100
B 72 78 56 70 75 78 80 98 100 100 98 99 99 100
B 78 76 76 66 68 70 74 99 100 100 99 100 100 99
B 80 88 74 68 70 72 72 100 100 100 100 100 100 100
B 78 90 75 70 70 70 75 100 100 100 100 100 99 99
B 80 98 76 70 72 70 76 99 100 100 99 100 100 100
B 75 96 78 68 66 64 70 100 100 100 100 100 100
B 78 98 68 66 64 66 68 100 100 100 100 100 99 100
B 74 94 66 65 62 60 64 99 100 100 98 98 100 100
B 82 92 70 65 64 66 68 100 100 100 100 100 99 99
B 72 86 78 76 75 76 86 99 100 100 98 100 100 100
B 76 85 74 70 68 72 76 99 100 100 100 100 100 100
B 88 88 72 68 70 70 74 100 100 100 100 100 100 98
L 76 80 90 88 80 84 86 100 100 100 100 100 98 100
L 80 88 88 86 86 80 88 100 100 100 100 100 100 100
L 75 90 78 76 78 74 80 95 100 100 98 99 100 100
L 99 94 88 65 68 78 90 100 100 100 100 100 100 100
L 76 98 90 88 90 86 88 100 100 100 100 100 100 100
L 96 96 80 82 80 86 84 98 100 100 98 100 98 100
L 86 88 98 96 98 96 94 100 100 100 100 100 100 98
L 84 84 99 90 92 86 88 100 100 100 100 100 100 100
L 88 85 100 95 92 88 90 100 100 100 100 100 100 99
L 86 88 88 90 92 86 88 100 100 100 100 100 100 100
L 83 86 90 86 88 84 86 99 100 100 99 100 100 98
L 93 85 92 84 82 80 80 100 100 100 100 100 98 100
L 99 90 96 90 92 88 90 100 100 100 100 100 100 99
L 93 98 98 86 88 84 86 99 100 100 99 100 100 100
L 84 95 94 84 86 84 90 100 100 100 100 100 100 98
L 79 100 88 82 80 82 90 100 100 100 100 100 98 100
L 78 98 60 76 80 82 80 99 100 100 94 98 100 99
L 98 96 90 82 78 80 88 100 100 100 100 100 100 100
L 86 88 85 84 80 82 86 98 100 100 98 100 98 100
L 98 90 86 80 82 80 88 100 100 100 100 100 100 99
L 91 85 84 86 88 86 90 100 100 100 100 100 100 100
L 81 86 78 80 82 80 84 100 100 100 100 100 98 100
L 86 80 80 78 80 82 86 100 100 100 100 100 100 100
L 86 86 82 80 82 80 86 95 100 100 98 99 100 100
L 93 84 86 84 86 83 84 100 100 100 100 100 100 98
L 92 82 88 86 88 86 86 100 100 100 100 100 99 100
L 81 85 90 88 86 84 84 98 100 100 98 100 100 100
L 95 78 98 90 88 86 90 100 100 100 100 100 99 100
L 85 80 56 65 70 75 80 100 100 100 100 100 100 100
L 86 85 100 96 94 92 90 100 100 100 100 100 99 98
MAP SPO2
Group
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Sl.No.
B 2 2 13 75 3 6 135 Hypotension,Bradycardia
B 2 6 12 68 3 6 132
B 2 4 14 77 3 7 138 Shivering
B 1 6 14 68 4 5 125
B 1 6 15 78 3 6 136
B 2 4 13 69 3 7 129
B 2 2 13 79 3 6 136 Bradycardia
B 2 6 14 80 3 6 131
B 2 6 16 70 4 6 135
B 2 6 14 74 2 7 129
B 1 2 12 72 2 5 133 Hypotension
B 1 6 14 73 3 8 136
B 2 4 13 79 3 10 134
B 2 2 11 70 3 9 137 Hypotension,Nausea,Vomiting
B 1 2 12 75 4 8 133 Hypotension
B 2 6 14 74 3 7 136
B 2 4 13 77 3 7 137
B 2 4 13 78 3 6 136 Hypotension
B 2 2 13 78 3 6 138 Hypotension.Bradycardia
B 2 6 13 76 3 6 139
B 2 6 14 76 2 7 137 Shivering
B 2 4 14 75 3 6 136
B 2 4 15 74 3 5 138
B 2 6 12 77 3 6 135
B 2 4 15 73 2 6 128
B 2 4 13 72 3 6 133
B 2 4 14 76 3 5 134
B 2 4 14 76 2 6 130 Nausea,vomiting
B 2 4 14 74 3 6 145
B 2 6 13 73 3 6 150 Shivering
L 2 6 11 65 4 14 108 Shivering
L 2 6 12 68 5 14 110
L 2 6 12 67 4 13 115
L 1 2 11 69 4 12 106 Hypotension,Bradycardia
L 2 6 12 69 4 15 98
L 2 6 11 71 5 14 96
L 2 4 12 68 6 12 93
L 1 6 11 70 4 14 94
L 2 6 11 68 4 12 90
L 2 4 13 73 4 12 110
L 2 6 11 65 4 12 115
L 1 6 12 64 5 6 115
L 2 6 11 70 4 7 108
L 3 4 3 72 5 12 100
L 2 6 12 65 4 8 108
L 2 6 11 70 6 12 86
L 3 4 12 73 4 9 87 Nausea,vomiting
L 2 6 13 70 6 12 96
L 2 6 12 65 9 98
L 2 6 13 75 5 10 96
L 2 4 12 73 6 13 103
L 2 6 12 67 5 12 92
L 3 6 11 70 4 11 88
L 2 6 13 65 6 11 84
L 2 4 11 75 5 11 98
L 2 4 11 64 4 12 99 Nausea,vomiting
L 2 4 12 72 3 12 108
L 2 6 13 71 4 13 106
L 3 2 11 67 3 12 110 Hypotension
L 2 6 11 72 4 14 115
Duration 
of motor 
block 
(min)
Side effects
Time of 
Once of 
sensory 
black 
(min)
Maximu
m 
Sensor 
level
Time to 
reach 
maximu
m  
sensory 
block( 
(min)
Time to 
two 
segment 
regressio
n 
sensory(
min)
Time to 
onset of 
motor 
block 
(min)
Time for 
maximu
m 
mottor 
(min)
Group
